| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 43598-0344-31 | 43598-0344 | Imatinib | Imatinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 15, 2020 | In Use | |
| 54868-5289-02 | 54868-5289 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 7, 2005 | Jun 30, 2013 | No Longer Used | |
| 00078-0526-87 | 00078-0526 | Nilotinib | Tasigna | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 29, 2007 | In Use | |
| 64679-0793-01 | 64679-0793 | imatinib mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 17, 2019 | In Use | |
| 60505-3801-07 | 60505-3801 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
| 67184-0532-02 | 67184-0532 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 21, 2022 | In Use | |
| 51991-0376-05 | 51991-0376 | IMATINIB MESYLATE | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | Mar 31, 2023 | No Longer Used |
| 70771-1902-06 | 70771-1902 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 47335-0475-83 | 47335-0475 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
| 70771-1394-09 | 70771-1394 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
| 66993-0236-30 | 66993-0236 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 3, 2024 | In Use | |
| 60505-2900-03 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
| 13668-0710-91 | 13668-0710 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 16, 2025 | In Use | |
| 59651-0240-90 | 59651-0240 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jul 23, 2020 | In Use | |
| 47335-0475-13 | 47335-0475 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
| 00480-5103-06 | 00480-5103 | Dasatinib | Dasatinib | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 18, 2025 | In Use | |
| 68180-0391-06 | 68180-0391 | IMATINIB | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jul 8, 2019 | In Use | |
| 72819-0186-03 | 72819-0186 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 1, 2022 | In Use | |
| 60505-3802-08 | 60505-3802 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
| 00003-0857-22 | 00003-0857 | Dasatinib | Sprycel | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 28, 2010 | In Use | |
| 69097-0031-74 | 69097-0031 | Nilotinib | Nilotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 18, 2025 | In Use | |
| 59651-0542-60 | 59651-0542 | DASATINIB | DASATINIB | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 43598-0599-60 | 43598-0599 | Dasatinib | Dasatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 64679-0794-03 | 64679-0794 | imatinib mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 17, 2019 | In Use | |
| 50268-0426-12 | 50268-0426 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 24, 2017 | In Use |
Found 12159 results — Export these results
Home